Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
